# FLuticasone in cOvid Treatment (FLOT)

> **NCT05054322** · PHASE2,PHASE3 · UNKNOWN · sponsor: **University of Medicine and Pharmacy at Ho Chi Minh City** · enrollment: 500 (estimated)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Fluticasone Propionate

## Key facts

- **NCT ID:** NCT05054322
- **Lead sponsor:** University of Medicine and Pharmacy at Ho Chi Minh City
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-22
- **Primary completion:** 2022-01-31
- **Final completion:** 2022-08-30
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2021-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05054322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05054322, "FLuticasone in cOvid Treatment (FLOT)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05054322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*